The FDA is also reviewing a lower 180mg maintenance dose. Thomas Hudson, AbbVie's chief scientific officer, said Skyrizi is the first new drug to be approved by the FDA for moderate-to-severe ...
Skyrizi is approved for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. AbbVie said the annual wholesale cost for maintenance dosing of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback